Opportunity Information: Apply for PA 12 281
Apply for PA 12 281
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Sep 10, 2012 and posted on Sep 10, 2012.
- Applicants must submit their applications by Jan 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Private institutions of higher education For profit organizations other than small businesses Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Special district governments Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Public housing authorities/Indian housing authorities State governments Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PA 12 281, titled "HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01)," is a discretionary grant program designed to support research that tackles persistent HIV/AIDS health disparities in the United States. Even with major improvements in HIV treatment and prevention and overall reductions in HIV related illness and death, the burden of HIV is still unevenly distributed, with certain groups continuing to face higher rates of infection and worse outcomes. This announcement focuses on understanding and reducing the ways drug use and drug abuse contribute to HIV risk, transmission, and long term health impacts in vulnerable populations, especially racial and ethnic minorities, men who have sex with men (MSM), and youth. The overarching goal is to generate practical evidence that can reduce new infections and improve the health and well being of people living with HIV.
A central priority of the program is research that clarifies how drug abuse fuels HIV acquisition and transmission, including both injection and non injection drug use. That means studies can examine classic transmission pathways associated with injection drug use, such as needle sharing, as well as risk mechanisms linked to non injection substances, such as impaired decision making, increased sexual risk behaviors, or patterns of use that shape exposure within social settings. Projects are expected to focus on vulnerable groups in the US context and to examine the specific behavioral, social, and environmental pathways through which substance use intersects with HIV risk.
In addition to prevention focused work, the FOA encourages studies on HIV disease progression and outcomes among people who use drugs or have substance use disorders. This includes research on how drug use may affect engagement in care, adherence to antiretroviral therapy, viral suppression, comorbidities, and broader health outcomes over time. The intent is not only to document disparities, but to explain why they occur and how to interrupt the mechanisms that drive poorer health trajectories.
Another major emphasis is intervention development and improvement, with a strong preference for comprehensive, integrated approaches. This can include creating or refining prevention and treatment strategies that address HIV and substance use together rather than in isolation, recognizing that fragmented services often fail the very populations most affected. Integrated interventions might combine HIV testing or prevention services with substance use treatment, mental health supports, adherence interventions, or navigation services that help people move across systems of care. The FOA is also open to interventions tailored for specific populations, settings, or stages of risk, as long as the work is grounded in evidence and designed to yield actionable outcomes.
The announcement also highlights implementation oriented research aimed at improving the availability, delivery, and quality of evidence based HIV prevention and treatment services across a variety of real world settings. In practice, this invites studies that look at how proven interventions can be adopted, scaled, and sustained in clinics, community programs, substance use treatment programs, correctional or transitional settings, schools or youth serving organizations, and other service environments where vulnerable populations receive care. The focus is on reducing gaps between what is known to work and what is actually delivered, including barriers related to staffing, training, referral pathways, care coordination, stigma, and resource constraints.
A distinctive feature of this FOA is its explicit interest in organizational, structural, and community level drivers of disparities. Rather than limiting research to individual behavior, it encourages applicants to examine broader forces such as social and sexual networks, drug using networks, community norms, access to prevention tools and treatment, and the ways institutions and systems influence risk and outcomes. This can include studying how network dynamics shape exposure and transmission, how community level stigma or discrimination affects service use, and how structural conditions influence both drug use patterns and HIV vulnerability. The intent is to support research that can inform interventions at multiple levels, including policy, organizational practice, and community strategy.
From an administrative standpoint, this opportunity used the NIH R01 funding mechanism, which is typically intended for substantial research projects that can support multi year programs of work. The program falls under CFDA 93.279, Drug Abuse and Addiction Research Programs, and was posted on September 10, 2012. It did not require cost sharing or matching. The original and final application due date listed for this specific announcement was January 7, 2016, with the archive date of February 7, 2016, meaning the FOA is no longer active but remains a useful reference for the kind of research NIH sought in this area.
Eligibility was broad and included many types of US based organizations. Eligible applicants included public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for profit organizations (including small businesses), and multiple levels of government such as state, county, city or township, special district governments, and public housing authorities. The eligibility list also explicitly referenced mission focused institutions and community anchored entities, such as Historically Black Colleges and Universities (HBCUs), Hispanic serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, and Asian American Native American Pacific Islander serving institutions (AANAPISI). Faith based and community based organizations and eligible federal agencies were also included. However, non US entities were not eligible to apply, and foreign components were not allowed under NIH policy as stated in the announcement.
The sponsoring agency was the National Institutes of Health, and the full archived announcement was available through the NIH grants guide at the link provided in the notice. For technical issues accessing the announcement, the contact listed was the NIH Office of Extramural Research (OER) webmaster. Overall, the funding opportunity aimed to strengthen the evidence base on how drug use intersects with HIV disparities and to move the field toward interventions and service delivery strategies that are effective, integrated, and responsive to the realities faced by vulnerable populations in the United States.
Frequently Asked Questions (FAQs)
What is NIH PA-12-281?
PA-12-281 is an NIH Funding Opportunity Announcement (FOA) titled "HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01)." It was a discretionary grant program supporting research on persistent HIV/AIDS health disparities in the United States, with a specific focus on how drug use and drug abuse affect HIV risk, transmission, and long-term health outcomes in vulnerable populations.
What is the main goal of this funding opportunity?
The overarching goal was to generate practical, actionable evidence to reduce new HIV infections and improve health and well-being among people living with HIV, especially in groups experiencing disproportionate burden and worse outcomes.
Is this FOA currently active?
No. The FOA is archived and no longer active. The final (and original) application due date listed for this announcement was January 7, 2016, and the archive date was February 7, 2016.
What NIH funding mechanism did this opportunity use?
This opportunity used the NIH R01 mechanism, which is typically intended for substantial research projects that can support multi-year programs of work.
What CFDA number was associated with this program?
The program fell under CFDA 93.279, Drug Abuse and Addiction Research Programs.
Which populations did the FOA emphasize as "vulnerable populations"?
The FOA emphasized research in the U.S. context focused especially on racial and ethnic minorities, men who have sex with men (MSM), and youth, recognizing that HIV burden remains unevenly distributed across groups.
What types of HIV prevention-related research were encouraged?
The FOA prioritized research that clarifies how drug abuse fuels HIV acquisition and transmission. This included both injection and non-injection drug use and the specific behavioral, social, and environmental pathways through which substance use intersects with HIV risk.
Does the FOA focus only on injection drug use?
No. While it included classic transmission pathways related to injection drug use (such as needle sharing), it also explicitly included non-injection substance use and associated risk mechanisms, such as impaired decision-making, increased sexual risk behaviors, and patterns of use in social settings that may influence exposure.
What kinds of research questions related to non-injection drug use fit this FOA?
Projects could examine how non-injection substances contribute to HIV risk and transmission through mechanisms like decision-making impairment, increased sexual risk behavior, and use patterns within social environments that shape exposure and vulnerability.
Did the FOA support research on HIV disease progression and outcomes?
Yes. In addition to prevention-focused work, the FOA encouraged studies on HIV disease progression and outcomes among people who use drugs or have substance use disorders.
What HIV care and treatment outcomes were mentioned as relevant?
The FOA referenced outcomes such as engagement in care, adherence to antiretroviral therapy, viral suppression, comorbidities, and broader health outcomes over time, particularly as they relate to drug use and substance use disorders.
Was the intent only to document disparities?
No. The FOA emphasized not just documenting disparities, but explaining why they occur and identifying ways to interrupt the mechanisms that drive poorer health trajectories.
What kind of intervention research did the FOA encourage?
The FOA emphasized intervention development and improvement, with a strong preference for comprehensive, integrated approaches that address HIV and substance use together rather than separately.
What does "integrated interventions" mean in the context of this FOA?
Integrated interventions could combine HIV testing or prevention services with substance use treatment, mental health supports, adherence interventions, and/or navigation services that help people move across systems of care. The FOA emphasized integrated approaches because fragmented services often fail populations most affected.
Were tailored interventions for specific settings or populations allowed?
Yes. The FOA was open to interventions tailored to specific populations, settings, or stages of risk, as long as the work was grounded in evidence and designed to yield actionable outcomes.
Did this FOA include implementation-oriented research?
Yes. The FOA highlighted implementation-oriented research aimed at improving the availability, delivery, and quality of evidence-based HIV prevention and treatment services in real-world settings.
What kinds of real-world settings were mentioned for implementation research?
Examples included clinics, community programs, substance use treatment programs, correctional or transitional settings, schools or youth-serving organizations, and other service environments where vulnerable populations receive care.
What types of implementation barriers did the FOA point to?
The FOA noted barriers contributing to gaps between what is known to work and what is delivered in practice, including staffing, training, referral pathways, care coordination, stigma, and resource constraints.
Did the FOA encourage research beyond individual-level behavior?
Yes. A distinctive feature of the FOA was its explicit interest in organizational, structural, and community-level drivers of disparities, not only individual behavior.
What broader drivers of HIV disparities were highlighted?
The FOA highlighted factors such as social and sexual networks, drug-using networks, community norms, access to prevention tools and treatment, and the role of institutions and systems in influencing risk and outcomes.
How did the FOA suggest networks could be studied?
The FOA encouraged examining how network dynamics shape exposure and transmission, including how social, sexual, and drug-using networks may influence HIV vulnerability and outcomes.
Did the FOA mention stigma or discrimination?
Yes. It referenced studying how community-level stigma or discrimination can affect service use and contribute to disparities.
Was cost sharing or matching required?
No. The FOA stated that it did not require cost sharing or matching.
Who was eligible to apply?
Eligibility was broad and included many types of U.S.-based organizations, such as public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses), and multiple levels of government.
What types of government entities were listed as eligible?
Eligible government entities included state, county, city or township governments, special district governments, and public housing authorities.
Were mission-focused and community-anchored institutions explicitly included?
Yes. The eligibility list explicitly referenced Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and Asian American Native American Pacific Islander-serving institutions (AANAPISI).
Were faith-based and community-based organizations eligible?
Yes. Faith-based and community-based organizations were included among eligible applicants.
Were federal agencies eligible to apply?
Yes. The eligibility information stated that eligible federal agencies were included.
Could non-U.S. organizations apply?
No. Non-U.S. entities were not eligible to apply under this announcement.
Were foreign components allowed?
No. Foreign components were not allowed under NIH policy as stated in the announcement.
Which agency sponsored this opportunity?
The sponsoring agency was the National Institutes of Health (NIH).
When was this FOA posted?
The FOA was posted on September 10, 2012.
Where could applicants find the full announcement?
The full archived announcement was available through the NIH Grants Guide at the link provided in the notice.
Who was listed as the contact for technical issues accessing the FOA?
For technical issues accessing the announcement, the contact listed was the NIH Office of Extramural Research (OER) webmaster.
What kinds of project outcomes did NIH appear to be looking for?
Based on the FOA description, NIH sought work designed to yield actionable outcomes, including evidence that can reduce new infections, improve HIV-related health outcomes, and support integrated interventions and service delivery strategies that are effective and responsive to real-world needs in vulnerable U.S. populations.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Reintroduce California Red Legged Frog and Enhance Frog and Salmon Habitat in Redwood Creek
Previous opportunity: HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 281
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 281) also looked into and applied for these:
| Funding Opportunity |
|---|
| AIDS Science Track Award for Research Transition (R03) Apply for PA 12 282 Funding Number: PA 12 282 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Revisions for Early Stage Development of Informatics Technology (R01) Apply for PAR 12 286 Funding Number: PAR 12 286 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Advanced Development of Informatics Technology (U24) Apply for PAR 12 287 Funding Number: PAR 12 287 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Early Stage Development of Informatics Technology (U01) Apply for PAR 12 288 Funding Number: PAR 12 288 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Revisions for Early Stage Development of Informatics Technology (U01) Apply for PAR 12 289 Funding Number: PAR 12 289 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions for Early Stage Development of Informatics Technology (P01) Apply for PAR 12 290 Funding Number: PAR 12 290 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Research Answers to NCIs Provocative Questions Group A (R01) Apply for RFA CA 12 015 Funding Number: RFA CA 12 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group A (R21) Apply for RFA CA 12 016 Funding Number: RFA CA 12 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions Group B (R01) Apply for RFA CA 12 017 Funding Number: RFA CA 12 017 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group B (R21) Apply for RFA CA 12 018 Funding Number: RFA CA 12 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions Group C (R01) Apply for RFA CA 12 019 Funding Number: RFA CA 12 019 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group C (R21) Apply for RFA CA 12 020 Funding Number: RFA CA 12 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions Group D (R01) Apply for RFA CA 12 021 Funding Number: RFA CA 12 021 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group D (R21) Apply for RFA CA 12 022 Funding Number: RFA CA 12 022 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014 (P50) Apply for PAR 12 296 Funding Number: PAR 12 296 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R01) Apply for PA 12 293 Funding Number: PA 12 293 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R03) Apply for PA 12 294 Funding Number: PA 12 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 12 295 Funding Number: PA 12 295 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Mechanism for Time Sensitive Drug Abuse Research (R21) Apply for PAR 12 297 Funding Number: PAR 12 297 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Cancer Center Support Grants (CCSGs) for NCI designated Cancer Centers (P30) Apply for PAR 12 298 Funding Number: PAR 12 298 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 281", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.